China (Mainland)
Diamondsupplier 
943319-70-8 CAS NO.943319-70-8
- FOB Price: USD: 500.00-500.00 /Kilogram Get Latest Price
- Min.Order: 100 Gram
- Payment Terms: L/C,D/A,D/P,T/T,MoneyGram,Other
- Available Specifications:
99%(50-100)Kilogram
- Product Details
Keywords
- 943319-70-8
- 943319-70-8
- 943319-70-8
Quick Details
- ProName: 943319-70-8
- CasNo: 943319-70-8
- Molecular Formula: C29H27F3N6O
- Appearance: white powder
- Application: anti-cancer
- DeliveryTime: in 7 days
- PackAge: 100G/bag
- Port: Shanghai/beijing/Tianjin
- ProductionCapacity: 10 Metric Ton/Year
- Purity: 99%
- Storage: Room temperature
- Transportation: Regular transportation
- LimitNum: 100 Gram
- Related Substances: 0.1%
- Residue on Ignition: 0.5%
- Heavy Metal: 10ppm
- Valid Period: 2 years
Superiority
Why is SINOWAY:
1) Specialized in pharmaceutical and healthcare industrial for 34 years.
2) ISO 9001:2015 & SGS audited supplier .
3) Accept various payment terms : T.T 30-60 days.
4) We have warehouse in USA with quickly shipment .
5) We can do different terms of FOB ,CIF/CIP ,DDP ...
Our Advantange of Ponatinib Base CAS 943319-70-8:
Best Quality and Competitive price and Enough Stock
Details
Basic information of Ponatinib Base CAS 943319-70-8
| Name | Ponatinib Base |
| CAS | 943319-70-8 |
| MF | C29H27F3N6O |
COA of Ponatinib Base CAS 943319-70-8
Use of Ponatinib Base CAS 943319-70-8
Ponatinib is an anti-cancer drug.In December 2012, it was approved for marketing by FDA in the United States for the treatment of adult chronic myelogenous leukemia (CML) and "Philadelphia chromosome positive" (Ph+) acute lymphoblastic leukemia (ALL).It is primarily used to treat patients who have not responded to dasatinib or nilotinib therapy, or who cannot tolerate dasatinib or nilotinib, and patients with Chemicalbook who are not suitable for subsequent treatment with imatinib.It can also be used to treat patients with a genetic mutation (the "T315I mutation") that makes them resistant to imatinib, dasatinib or nilotinib.Also used to treat CML and Ph+ALL in adults who have not been treated with other TKIs.It is currently the only marketed drug that is effective against the BCR-ABL kinase T315I mutation.Panatinib was approved in the European Union in July 2013 through a centralized approval process.
